{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:15:45Z","timestamp":1793812545641,"version":"4.6.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis B virus (HBV) infection causes acute hepatitis B (AHB), chronic hepatitis B (CHB), liver cirrhosis (LC), and eventually hepatocellular carcinoma (HCC). The presence of hepatitis B e antigen (HBeAg) in the serum generally indicates ongoing viral replication and disease progression. However, the mechanism by which HBeAg regulates HBV infection remains unclear. Interferons (IFNs) are pleiotropic cytokines that participate in host innate immunity. After binding to receptors, IFNs activate the JAK\/STAT pathway to stimulate expression of IFN-stimulated genes (ISGs), leading to induction of antiviral responses. Here, we revealed that HBeAg represses IFN\/JAK\/STAT signaling to facilitate HBV replication. Initially, HBeAg stimulates the expression of suppressor of cytokine signaling 2 (SOCS2). Subsequently, SOCS2 impairs IFN\/JAK\/STAT signaling through reducing the stability of tyrosine kinase 2 (TYK2), downregulating the expression of type I and III IFN receptors, attenuating the phosphorylation and nucleus translocation of STAT1. Finally, SOCS2 inhibits the expression of ISGs, which leads to the repression of IFN action and facilitation of viral replication. These results demonstrate an important role of HBeAg in the regulation of IFN action, and provide a possible molecular mechanism by which HBV resists the IFN therapy and maintains persistent infection.<\/jats:p>","DOI":"10.1038\/s41598-017-01773-6","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T17:00:16Z","timestamp":1493917216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action"],"prefix":"10.1038","volume":"7","author":[{"given":"Yi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingle","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"key":"1773_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","volume":"64","author":"C Seeger","year":"2000","unstructured":"Seeger, C. & Mason, W. S. Hepatitis B virus biology. Microbiol Mol Biol Rev 64, 51\u201368 (2000).","journal-title":"Microbiol Mol Biol Rev"},{"key":"1773_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1126\/science.6264599","volume":"213","author":"P Tiollais","year":"1981","unstructured":"Tiollais, P., Charnay, P. & Vyas, G. N. Biology of hepatitis B virus. Science 213, 406\u2013411 (1981).","journal-title":"Science"},{"key":"1773_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nri1573","volume":"5","author":"B Rehermann","year":"2005","unstructured":"Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5, 215\u2013229 (2005).","journal-title":"Nat Rev Immunol"},{"key":"1773_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","volume":"14","author":"CE Samuel","year":"2001","unstructured":"Samuel, C. E. Antiviral actions of interferons. Clin Microbiol Rev 14, 778\u2013809 (2001).","journal-title":"Clin Microbiol Rev"},{"key":"1773_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1359-6101(00)00027-7","volume":"12","author":"DE Levy","year":"2001","unstructured":"Levy, D. E. & Garcia-Sastre, A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 12, 143\u2013156 (2001).","journal-title":"Cytokine Growth Factor Rev"},{"key":"1773_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0092-8674(94)90154-6","volume":"77","author":"D Novick","year":"1994","unstructured":"Novick, D., Cohen, B. & Rubinstein, M. The human interferon alpha\/beta receptor: characterization and molecular cloning. Cell 77, 391\u2013400 (1994).","journal-title":"Cell"},{"key":"1773_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4, 63\u201368 (2003).","journal-title":"Nat Immunol"},{"key":"1773_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4049\/jimmunol.1300252","volume":"192","author":"Y Cao","year":"2014","unstructured":"Cao, Y. et al. IL-27, a cytokine, and IFN-lambda1, a type III IFN, are coordinated to regulate virus replication through type I IFN. J Immunol 192, 691\u2013703 (2014).","journal-title":"J Immunol"},{"key":"1773_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko, S. V. et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4, 69\u201377 (2003).","journal-title":"Nat Immunol"},{"key":"1773_CR10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nrd2422","volume":"6","author":"EC Borden","year":"2007","unstructured":"Borden, E. C. et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6, 975\u2013990 (2007).","journal-title":"Nat Rev Drug Discov"},{"key":"1773_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5, 375\u2013386 (2005).","journal-title":"Nat Rev Immunol"},{"key":"1773_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1136\/gut.30.8.1116","volume":"30","author":"MG Brook","year":"1989","unstructured":"Brook, M. G. et al. Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 30, 1116\u20131122 (1989).","journal-title":"Gut"},{"key":"1773_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/1096-9071(200103)63:3<217::AID-JMV1003>3.0.CO;2-2","volume":"63","author":"RA Heijtink","year":"2001","unstructured":"Heijtink, R. A., Janssen, H. L., Hop, W. C., Osterhaus, A. D. & Schalm, S. W. Interferon-alpha therapy for chronic hepatitis B: early response related to pre-treatment changes in viral replication. J Med Virol 63, 217\u2013219 (2001).","journal-title":"J Med Virol"},{"key":"1773_CR14","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1002\/hep.22956","volume":"49","author":"R Perrillo","year":"2009","unstructured":"Perrillo, R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 49, S103\u2013111 (2009).","journal-title":"Hepatology"},{"key":"1773_CR15","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1073\/pnas.88.7.2888","volume":"88","author":"GR Foster","year":"1991","unstructured":"Foster, G. R. et al. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci USA 88, 2888\u20132892 (1991).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1773_CR16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1286-4579(02)00012-6","volume":"4","author":"Y Ilan","year":"2002","unstructured":"Ilan, Y. Immune downregulation leads to upregulation of an antiviral response: a lesson from the hepatitis B virus. Microbes Infect 4, 1317\u20131326 (2002).","journal-title":"Microbes Infect"},{"key":"1773_CR17","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/jvi.61.10.3322-3325.1987","volume":"61","author":"C Chang","year":"1987","unstructured":"Chang, C. et al. Expression of the precore region of an avian hepatitis B virus is not required for viral replication. J Virol 61, 3322\u20133325 (1987).","journal-title":"J Virol"},{"key":"1773_CR18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0016-5085(80)90130-4","volume":"79","author":"G Realdi","year":"1980","unstructured":"Realdi, G. et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 79, 195\u2013199 (1980).","journal-title":"Gastroenterology"},{"key":"1773_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1053\/jhep.2003.50453","volume":"38","author":"D Milich","year":"2003","unstructured":"Milich, D. & Liang, T. J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38, 1075\u20131086 (2003).","journal-title":"Hepatology"},{"key":"1773_CR20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.4049\/jimmunol.160.4.2013","volume":"160","author":"DR Milich","year":"1998","unstructured":"Milich, D. R., Chen, M. K., Hughes, J. L. & Jones, J. E. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 160, 2013\u20132021 (1998).","journal-title":"J Immunol"},{"key":"1773_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/hep.510260329","volume":"26","author":"MJ Mphahlele","year":"1997","unstructured":"Mphahlele, M. J. et al. Transmission of a homogenous hepatitis B virus population of A1896-containing strains leading to mild resolving acute hepatitis and seroconversion to hepatitis B e antigen antibodies in an adult. Hepatology 26, 743\u2013746 (1997).","journal-title":"Hepatology"},{"key":"1773_CR22","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/jvi.71.3.2192-2201.1997","volume":"71","author":"DR Milich","year":"1997","unstructured":"Milich, D. R., Schodel, F., Hughes, J. L., Jones, J. E. & Peterson, D. L. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 71, 2192\u20132201 (1997).","journal-title":"J Virol"},{"key":"1773_CR23","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.22751","volume":"49","author":"J Wu","year":"2009","unstructured":"Wu, J. et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49, 1132\u20131140 (2009).","journal-title":"Hepatology"},{"key":"1773_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/hep.21482","volume":"45","author":"K Visvanathan","year":"2007","unstructured":"Visvanathan, K. et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45, 102\u2013110 (2007).","journal-title":"Hepatology"},{"key":"1773_CR25","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1128\/CVI.00396-05","volume":"13","author":"SM Riordan","year":"2006","unstructured":"Riordan, S. M., Skinner, N., Kurtovic, J., Locarnini, S. & Visvanathan, K. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol 13, 972\u2013974 (2006).","journal-title":"Clin Vaccine Immunol"},{"key":"1773_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/43206","volume":"387","author":"R Starr","year":"1997","unstructured":"Starr, R. et al. A family of cytokine-inducible inhibitors of signalling. Nature 387, 917\u2013921 (1997).","journal-title":"Nature"},{"key":"1773_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nri2093","volume":"7","author":"A Yoshimura","year":"2007","unstructured":"Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7, 454\u2013465 (2007).","journal-title":"Nat Rev Immunol"},{"key":"1773_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cytogfr.2008.08.006","volume":"19","author":"J Piessevaux","year":"2008","unstructured":"Piessevaux, J., Lavens, D., Peelman, F. & Tavernier, J. The many faces of the SOCS box. Cytokine Growth Factor Rev 19, 371\u2013381 (2008).","journal-title":"Cytokine Growth Factor Rev"},{"key":"1773_CR29","doi-asserted-by":"publisher","first-page":"35056","DOI":"10.1074\/jbc.273.52.35056","volume":"273","author":"MM Song","year":"1998","unstructured":"Song, M. M. & Shuai, K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 273, 35056\u201335062 (1998).","journal-title":"J Biol Chem"},{"key":"1773_CR30","doi-asserted-by":"publisher","first-page":"14090","DOI":"10.1128\/JVI.01346-14","volume":"88","author":"MA Steffensen","year":"2014","unstructured":"Steffensen, M. A. et al. Suppressors of cytokine signaling 1 and 3 are upregulated in brain resident cells in response to virus-induced inflammation of the central nervous system via at least two distinctive pathways. J Virol 88, 14090\u201314104 (2014).","journal-title":"J Virol"},{"key":"1773_CR31","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/jvi.64.3.1298-1303.1990","volume":"64","author":"H Okamoto","year":"1990","unstructured":"Okamoto, H. et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 64, 1298\u20131303 (1990).","journal-title":"J Virol"},{"key":"1773_CR32","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0140-6736(89)90713-7","volume":"2","author":"WF Carman","year":"1989","unstructured":"Carman, W. F. et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2, 588\u2013591 (1989).","journal-title":"Lancet"},{"key":"1773_CR33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1128\/JCM.43.1.254-258.2005","volume":"43","author":"TL Waltz","year":"2005","unstructured":"Waltz, T. L. et al. Development of a molecular-beacon assay to detect the G1896A precore mutation in hepatitis B virus-infected individuals. J Clin Microbiol 43, 254\u2013258 (2005).","journal-title":"J Clin Microbiol"},{"key":"1773_CR34","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1073\/pnas.0401771101","volume":"101","author":"S Wieland","year":"2004","unstructured":"Wieland, S., Thimme, R., Purcell, R. H. & Chisari, F. V. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101, 6669\u20136674 (2004).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1773_CR35","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.284.5415.825","volume":"284","author":"LG Guidotti","year":"1999","unstructured":"Guidotti, L. G. et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825\u2013829 (1999).","journal-title":"Science"},{"key":"1773_CR36","doi-asserted-by":"publisher","first-page":"10412","DOI":"10.1128\/JVI.00111-14","volume":"88","author":"S Jegaskanda","year":"2014","unstructured":"Jegaskanda, S. et al. Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen. J Virol 88, 10412\u201310420 (2014).","journal-title":"J Virol"},{"key":"1773_CR37","first-page":"39","volume":"350","author":"EB Wilson","year":"2011","unstructured":"Wilson, E. B. & Brooks, D. G. The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol 350, 39\u201365 (2011).","journal-title":"Curr Top Microbiol Immunol"},{"key":"1773_CR38","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/hep.25879","volume":"56","author":"J Martinet","year":"2012","unstructured":"Martinet, J. et al. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology 56, 1706\u20131718 (2012).","journal-title":"Hepatology"},{"key":"1773_CR39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jhep.2010.12.042","volume":"55","author":"T Lang","year":"2011","unstructured":"Lang, T. et al. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol 55, 762\u2013769 (2011).","journal-title":"J Hepatol"},{"key":"1773_CR40","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1074\/jbc.M409863200","volume":"280","author":"Y Qing","year":"2005","unstructured":"Qing, Y., Costa-Pereira, A. P., Watling, D. & Stark, G. R. Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J Biol Chem 280, 1849\u20131853 (2005).","journal-title":"J Biol Chem"},{"key":"1773_CR41","doi-asserted-by":"publisher","first-page":"33811","DOI":"10.1074\/jbc.M111.270207","volume":"286","author":"RA Piganis","year":"2011","unstructured":"Piganis, R. A. et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 286, 33811\u201333818 (2011).","journal-title":"J Biol Chem"},{"key":"1773_CR42","doi-asserted-by":"publisher","first-page":"6493","DOI":"10.1073\/pnas.100135197","volume":"97","author":"SE Nicholson","year":"2000","unstructured":"Nicholson, S. E. et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97, 6493\u20136498 (2000).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1773_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1743-422X-11-51","volume":"11","author":"LY Du","year":"2014","unstructured":"Du, L. Y. et al. Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment. Virol J 11, 51 (2014).","journal-title":"Virol J"},{"key":"1773_CR44","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2893.1995.tb00036.x","volume":"2","author":"T Aikawa","year":"1995","unstructured":"Aikawa, T. et al. Interferon-alpha 2a for chronic hepatitis B with e antigen or antibody:comparable antiviral effects on wild-type virus and precore mutant. J Viral Hepat 2, 243\u2013250 (1995).","journal-title":"J Viral Hepat"},{"key":"1773_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hep.1840150405","volume":"15","author":"G Fattovich","year":"1992","unstructured":"Fattovich, G. et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 15, 584\u2013589 (1992).","journal-title":"Hepatology"},{"key":"1773_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/(SICI)1096-9071(199601)48:1<8::AID-JMV2>3.0.CO;2-E","volume":"48","author":"X Zhang","year":"1996","unstructured":"Zhang, X., Zoulim, F., Habersetzer, F., Xiong, S. & Trepo, C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 48, 8\u201316 (1996).","journal-title":"J Med Virol"},{"key":"1773_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.1840100213","volume":"10","author":"MR Brunetto","year":"1989","unstructured":"Brunetto, M. R. et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 10, 198\u2013202 (1989).","journal-title":"Hepatology"},{"key":"1773_CR48","first-page":"42","volume":"22","author":"MR Brunetto","year":"1995","unstructured":"Brunetto, M. R. et al. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J Hepatol 22, 42\u201344 (1995).","journal-title":"J Hepatol"},{"key":"1773_CR49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0168-8278(92)90161-H","volume":"14","author":"G Pastore","year":"1992","unstructured":"Pastore, G. et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 14, 221\u2013225 (1992).","journal-title":"J Hepatol"},{"key":"1773_CR50","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/0016-5085(93)90903-P","volume":"105","author":"MR Brunetto","year":"1993","unstructured":"Brunetto, M. R. et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 105, 845\u2013850 (1993).","journal-title":"Gastroenterology"},{"key":"1773_CR51","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/hep.26064","volume":"57","author":"J Chen","year":"2013","unstructured":"Chen, J. et al. Hepatitis B virus polymerase impairs interferon-alpha-induced STA T activation through inhibition of importin-alpha5 and protein kinase C-delta. Hepatology 57, 470\u2013482 (2013).","journal-title":"Hepatology"},{"key":"1773_CR52","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1099\/vir.0.82959-0","volume":"88","author":"M Wu","year":"2007","unstructured":"Wu, M. et al. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 88, 3260\u20133269 (2007).","journal-title":"J Gen Virol"},{"key":"1773_CR53","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","volume":"79","author":"MD Robek","year":"2005","unstructured":"Robek, M. D., Boyd, B. S. & Chisari, F. V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79, 3851\u20133854 (2005).","journal-title":"J Virol"},{"key":"1773_CR54","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/hep.21312","volume":"44","author":"SE Doyle","year":"2006","unstructured":"Doyle, S. E. et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44, 896\u2013906 (2006).","journal-title":"Hepatology"},{"key":"1773_CR55","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.virusres.2007.03.006","volume":"126","author":"SH Hong","year":"2007","unstructured":"Hong, S. H. et al. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 126, 245\u2013249 (2007).","journal-title":"Virus Res"},{"key":"1773_CR56","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","volume":"131","author":"T Marcello","year":"2006","unstructured":"Marcello, T. et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887\u20131898 (2006).","journal-title":"Gastroenterology"},{"key":"1773_CR57","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4161\/cbt.7.7.6192","volume":"7","author":"SG Maher","year":"2008","unstructured":"Maher, S. G. et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK\/STAT signaling activity. Cancer Biol Ther 7, 1109\u20131115 (2008).","journal-title":"Cancer Biol Ther"},{"key":"1773_CR58","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"D Ganem","year":"2004","unstructured":"Ganem, D. & Prince, A. M. Hepatitis B virus infection\u2013natural history and clinical consequences. N Engl J Med 350, 1118\u20131129 (2004).","journal-title":"N Engl J Med"},{"key":"1773_CR59","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","volume":"334","author":"C Niederau","year":"1996","unstructured":"Niederau, C. et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334, 1422\u20131427 (1996).","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1773_CR60","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/0168-8278(91)91712-P","volume":"13","author":"HC Thomas","year":"1991","unstructured":"Thomas, H. C., Karayiannis, P. & Brook, G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. J Hepatol 13(Suppl 1), S4\u20137 (1991).","journal-title":"J Hepatol"},{"key":"1773_CR61","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJM199008023230503","volume":"323","author":"RP Perrillo","year":"1990","unstructured":"Perrillo, R. P. et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 323, 295\u2013301 (1990).","journal-title":"N Engl J Med"},{"key":"1773_CR62","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","volume":"146","author":"Y Ni","year":"2014","unstructured":"Ni, Y. et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146, 1070\u20131083 (2014).","journal-title":"Gastroenterology"},{"key":"1773_CR63","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1, e00049 (2012).","journal-title":"Elife"},{"key":"1773_CR64","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1096\/fj.11-187781","volume":"25","author":"Y Chen","year":"2011","unstructured":"Chen, Y. et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J 25, 4511\u20134521 (2011).","journal-title":"FASEB J"},{"key":"1773_CR65","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/jmv.22102","volume":"83","author":"RR Yang","year":"2011","unstructured":"Yang, R. R., Gui, X., Chen, X. Y. & Zhu, Y. Interference of replication between hepatitis B and C viruses in patients infected with HIV. J Med Virol 83, 1159\u20131164 (2011).","journal-title":"J Med Virol"},{"key":"1773_CR66","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.virol.2008.11.042","volume":"385","author":"LM Xia","year":"2009","unstructured":"Xia, L. M. et al. HBx protein induces expression of MIG and increases migration of leukocytes through activation of NF-kappaB. Virology 385, 335\u2013342 (2009).","journal-title":"Virology"},{"key":"1773_CR67","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.4049\/jimmunol.1100998","volume":"187","author":"Y Yu","year":"2011","unstructured":"Yu, Y. et al. Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. J Immunol 187, 4844\u20134860 (2011).","journal-title":"J Immunol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-01773-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-01773-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-01773-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:12:06Z","timestamp":1692792726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-01773-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-01773-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,11]]},"assertion":[{"value":"10 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1729"}}